language

Looking for reliable pharma & medical sourcing?

REQUEST QUOTE

Rely on 70+ years of group manufacturing strength, international certified products and full-chain after-service. Submit inquiry now.

Home

SSY Group Obtains Registration Approvals for Ceftizoxime Sodium for Injection (1.0g & 0.5g)

Release time:

2026-06-08

On June 8, SSY Group obtained registration approval documents for two specifications of Ceftizoxime Sodium for Injection (1.0g and 0.5g). Since the start of this year, the Group has secured 44 new product approvals, including 33 for finished preparations and 11 for APIs.

Ceftizoxime Sodium for Injection is classified as Class 4 chemical drug. It is indicated for lower respiratory tract infections, urinary tract infections, intra-abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and uncomplicated gonorrhea triggered by susceptible bacteria.

Guided by market demands in recent years, the Group has continuously optimized and expanded its portfolio of antibiotic preparations, building a serialized product line covering multiple dosage forms such as tablets, hard capsules, granules, lyophilized formulations and dry suspensions. On this basis, the Group keeps improving its comprehensive R&D capacity and market competitiveness in the antibiotic preparation sector to further strengthen its overall industrial advantages.

Up to now, a total of 187 product varieties and 249 specifications under the Group have passed or been deemed to have passed the Consistency Evaluation of Quality and Efficacy of Generic Drugs, steadily boosting market accessibility of its products.

TAG:

Golden Gate Pharma

Cefpodoxime Proxetil Dry Suspension (50mg) of SSY Group Granted Approval

Shijiazhuang No.4 Pharmaceutical Boosts Development of Modified Innovative Drugs